Patents by Inventor Nathalie Silvestre
Nathalie Silvestre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150165014Abstract: The present invention relates generally to immunogenic combinations comprising at least five antigens of a Mycobacterium species as well as fusion thereof and nucleic acid molecules encoding such combined antigens and fusion. The present invention also relates to nucleic acid molecules, vectors, host cells and compositions comprising or encoding said combinations of mycobacterial antigens and fusion polypeptides as well as to methods for recombinantly producing them. The present invention also relates to methods of using said combinations of mycobacterial antigens, fusion polypeptides, vectors, host cells, compositions particularly for inducing or stimulating an immune response against a Mycobacterium infection or any disease caused by or associated with a Mycobacterium infection.Type: ApplicationFiled: July 10, 2013Publication date: June 18, 2015Applicant: TRANSGENE SAInventors: Emmanuel Tupin, Romain Micol, Charles Antoine Coupet, Geneviève Inchaupse, Marie Gouanvic, Nathalie Silvestre, Jean-Baptiste Marchand, Cécile Beny
-
Patent number: 9024003Abstract: The present invention notably relates to novel recombinant telomerase reverse transcriptases, nucleic acid molecules coding them, cells comprising said nucleic acid molecule and use of these cells for the production of substance of interest.Type: GrantFiled: January 5, 2007Date of Patent: May 5, 2015Assignee: Transgene S.A.Inventors: Philippe Erbs, Jean-Marc Balloul, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20140287480Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.Type: ApplicationFiled: July 12, 2012Publication date: September 25, 2014Applicant: Transgene S.A.Inventors: Perrine Martin, Nathalie Silvestre, Jean-Baptiste Marchand
-
Patent number: 8809056Abstract: This invention relates to immortalized avian cells, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: GrantFiled: December 21, 2012Date of Patent: August 19, 2014Assignee: Transgene S.A.Inventors: Phillippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20130244246Abstract: This invention relates to immortalized avian cells, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: ApplicationFiled: December 21, 2012Publication date: September 19, 2013Applicant: TRANSGENE S.A.`Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Patent number: 8513018Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: GrantFiled: May 29, 2012Date of Patent: August 20, 2013Assignee: Transgene S.A.Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20130095557Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: ApplicationFiled: June 29, 2011Publication date: April 18, 2013Applicant: TRANSGENE S.A.Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Patent number: 8420103Abstract: A nucleic acid molecule encoding at least one papillomavirus E2 polypeptide, or a vector, an infectious viral particle or a therapeutic composition thereof is formulated into a drug product useful for treating a patient suffering from a persistent papillomavirus infection caused by at least one papillomavirus; particular such vectors are nucleic acid molecules containing a first nucleotide sequence encoding a papillomavirus E1 polypeptide and a second nucleotide sequence encoding a papillomavirus E2 polypeptide wherein the 3? portion of the first nucleotide which in the natural content is 100% identical to the 5? portion of the second nucleotide is modified so as to exhibit a percentage of identity between said portions of at most 75%.Type: GrantFiled: January 29, 2008Date of Patent: April 16, 2013Assignee: Transgene S.A.Inventors: Martine Baudin, Jean-Marc Balloul, Nathalie Silvestre
-
Patent number: 8361788Abstract: Immortalized avian cell lines containing E1A nucleic acid sequences are useful for the production of viruses and are particularly useful for the production of recombinant viral vectors which can be employed for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: GrantFiled: July 2, 2008Date of Patent: January 29, 2013Assignee: Transgene S.A.Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Patent number: 8357531Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: GrantFiled: July 2, 2010Date of Patent: January 22, 2013Assignee: Transgene S.A.Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20130011435Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.Type: ApplicationFiled: August 6, 2010Publication date: January 10, 2013Applicant: Transgene SAInventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt
-
Patent number: 8337859Abstract: The present invention provides a vector for expressing at least a first and a second nucleic acid molecules which exhibit a percentage of homology of approximately 80% or greater than 80% over a portion of 40 or more continuous nucleotides and wherein said first nucleic acid molecule and/or said second nucleic acid molecule is modified so as to reduce said percentage of homology to less than 75%. The present invention also relates to substantially isolated nucleic acid molecules comprising a nucleotide sequence as defined in any of SEQ ID NO: 9-15 and 66-69. It also provides a host cell and a pharmaceutical composition comprising such a nucleic acid molecule or vector as well as their use for therapeutic or preventive purposes.Type: GrantFiled: January 29, 2008Date of Patent: December 25, 2012Assignee: Transgene S.A.Inventors: Nathalie Silvestre, Doris Schmitt
-
Publication number: 20120251569Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.Type: ApplicationFiled: March 17, 2012Publication date: October 4, 2012Applicant: TRANSGENE SAInventors: Perrine Martin, Geneviève Inchauspe, Nathalie Silvestre, Doris Schmitt, Alexei Evlachev
-
Publication number: 20120238000Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: ApplicationFiled: May 29, 2012Publication date: September 20, 2012Applicant: Transgene S.A.Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20110008872Abstract: This invention relates to immortalized avian cells, including those deposited under accession numbers 09070701, 09070702, and 09070703 at the ECACC, and to the use of these cells for the production of viruses. The cells according to the invention are particularly useful for the production of recombinant viral vectors which can be used for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: ApplicationFiled: July 2, 2010Publication date: January 13, 2011Applicant: Transgene S.A.Inventors: Philippe ERBS, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20100303838Abstract: The present invention provides a vector for expressing at least a first and a second nucleic acid molecules which exhibit a percentage of homology of approximately 80% or greater than 80% over a portion of 40 or more continuous nucleotides and wherein said first nucleic acid molecule and/or said second nucleic acid molecule is modified so as to reduce said percentage of homology to less than 75%. The present invention also relates to substantially isolated nucleic acid molecules comprising a nucleotide sequence as defined in any of SEQ ID NO: 9-15 and 66-69. It also provides a host cell and a pharmaceutical composition comprising such a nucleic acid molecule or vector as well as their use for therapeutic or preventive purposes.Type: ApplicationFiled: January 29, 2008Publication date: December 2, 2010Applicant: Transgene S.A.Inventors: Nathalie Silvestre, Doris Schmitt
-
Publication number: 20100197010Abstract: Immortalized avian cell lines containing E1A nucleic acid sequences are useful for the production of viruses and are particularly useful for the production of recombinant viral vectors which can be employed for the preparation of therapeutic and/or prophylactic compositions for the treatment of animals and more particularly humans.Type: ApplicationFiled: July 2, 2008Publication date: August 5, 2010Inventors: Philippe Erbs, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20100173378Abstract: The present invention notably relates to novel recombinant telomerase reverse transcriptases, nucleic acid molecules coding them, cells comprising said nucleic acid molecule and use of these cells for the production of substance of interest.Type: ApplicationFiled: January 5, 2007Publication date: July 8, 2010Applicant: Transgene S.A.Inventors: Philippe Erbs, Jean-Marc Balloul, Marina Kapfer, Nathalie Silvestre
-
Publication number: 20100160227Abstract: The present invention provides novel peptides of specified sequence and their use as a signal peptide or a membrane-anchoring peptide. It also relates to chimeric polypeptide comprising one or more such peptides and a polypeptide of interest as well as nucleic acid molecules, vectors, infections vital particles and host cells encoding such peptides and chimeric polypeptides. The present invention also relates to a pharmaceutical composition comprising such elements and a pharmaceutically acceptable vehicle. The present invention also provides a method for recumbently producing a polypeptide using such peptides, especially for directing expression of a polypeptide of interest extracellularly or anchored at the surface of the plasma membrane.Type: ApplicationFiled: January 29, 2008Publication date: June 24, 2010Applicant: TRANSGENE S.A.Inventors: Nathalie Silvestre, Eric Jacobs
-
Publication number: 20100143408Abstract: A nucleic acid molecule encoding at least one papillomavirus E2 polypeptide, or a vector, an infectious viral particle or a therapeutic composition thereof is formulated into a drug product useful for treating a patient suffering from a persistent papillomavirus infection caused by at least one papillomavirus; particular such vectors are nucleic acid molecules containing a first nucleotide sequence encoding a papillomavirus E1 polypeptide and a second nucleotide sequence encoding a papillomavirus E2 polypeptide wherein the 3? portion of the first nucleotide which in the natural content is 100% identical to the 5? portion of the second nucleotide is modified so as to exhibit a percentage of identity between said portions of at most 75%.Type: ApplicationFiled: January 29, 2008Publication date: June 10, 2010Inventors: Martine Baudin, Jean-Marc Balloul, Nathalie Silvestre